Emerging Trends In AI In Biotech
ByGuadalupe Hayes-Mota, Former Forbes Councils Member.
for Forbes Business CouncilCOUNCIL POST | Membership (fee-based)
CEO & Founder, Healr Solutions​​​​​​​ | MIT Senior Lecturer | Corporate, Non-Profit, & Governmental Board Member.

Group of scientists analyzing medical data on laptop in the laboratory.
getty
The intersection of artificial intelligence (AI) and biotechnology is revolutionizing the healthcare landscape, offering opportunities for venture capitalists (VCs) to drive innovation and achieve significant returns on investment. This article delves into the key trends in AI in biotech and provides actionable strategies for VCs to navigate this dynamic sector.

As an executive leading biotech research and a founder of a biotech, I've witnessed firsthand the transformative potential of AI in this field. Additionally, my tenure as a researcher at the Robert Langer Lab at MIT, where I focused on drug discovery, and my role teaching bioethics and biotech business at MIT have given me a comprehensive understanding of the sector's intricacies.

It is crucial to explore these developments now because AI is at a pivotal point in its capacity to create new products that can significantly enhance individuals' health and well-being.

Personalized Medicine
Personalized medicine represents a shift from a one-size-fits-all approach to tailored treatments based on individual genetic profiles, lifestyles and environments. AI algorithms are central to this transformation, enabling the analysis of vast data to predict patient responses to treatments, thus enhancing efficacy and reducing adverse effects. Companies at the forefront of AI-driven personalized medicine, such as Tempus and Foundation Medicine, are developing platforms that offer custom cancer therapies, personalized treatment plans for rare diseases, and precision pharmacogenomics.

AI-Driven Drug Discovery
The traditional drug discovery process is time-consuming and costly, often taking over a decade and billions of dollars to bring a new drug to market. AI is streamlining this process by predicting the efficacy and safety of potential compounds with more speed and accuracy. AI models can analyze chemical databases to identify new drug candidates or repurpose existing drugs for new therapeutic uses. Companies leading the trend in drug discovery include Insilco Medicine and Atomwise. This trend is particularly promising for addressing unmet medical needs and accelerating the development of treatments for complex diseases.

Synthetic Biology
Companies are harnessing AI for gene editing, biomaterial production and synthetic pathways are at the forefront of synthetic biology. This combines principles of biology and engineering to design and construct new biological entities. AI optimizes synthetic biology processes, from designing genetic circuits to scaling up production. For example, Ginkgo Bioworks uses AI to design custom microorganisms for applications ranging from pharmaceuticals to industrial chemicals.

Regenerative Medicine
AI is transforming regenerative medicine by advancing the development of stem cell therapies and tissue engineering. AI algorithms assist in identifying optimal cell types, predicting cell behavior and personalized treatments, which is particularly relevant for conditions such as neurodegenerative diseases, heart failure and orthopedic injuries. Organovo, for instance, is leveraging AI to potentially improve the efficacy and scalability of regenerative therapies, developing next-generation treatments that offer the potential to restore function and improve the quality of life for patients.

symbol
00:00

03:12
Read More
Data Integration
One of the biggest challenges in healthcare is the integration of disparate data sources, including genomic, proteomic and clinical data. For AI to deliver meaningful insights, seamless data integration and interoperability are critical. Startups developing platforms facilitating comprehensive, longitudinal patient data analysis are vital enablers of AI in biotech. Companies like Flatiron Health are working on integrating diverse datasets to provide a holistic view of patient health, enabling more accurate diagnoses and personalized treatment plans. VCs should prioritize investments in companies that break down data silos and promote data interoperability, as this will enhance the utility and impact of AI-driven solutions.

Strategies For VCs
Focus on clinical validation.
Look at companies that prioritize clinical validation of their AI technologies. Clinical trials and real-world evidence not only enhance credibility but also accelerate market adoption. For example, Novartis’ CAR-T therapy, Kymriah, received the FDA’s accelerated approval for treating relapsed or refractory follicular lymphoma, thanks to the integration of real-world evidence (RWE) with clinical trials data from the Phase II ELARA trial. VCs should look for companies with robust clinical trial data and partnerships with leading healthcare institutions. This focus on validation ensures that the technologies being developed are innovative, clinically relevant and ready for deployment in real-world settings.

Foster collaborative ecosystems.
Encourage portfolio companies to build partnerships with academic institutions, healthcare providers and pharmaceutical companies to foster a collaborative ecosystem that accelerates research and development. These partnerships can provide access to valuable resources, including clinical data, research expertise and regulatory insights. For instance, companies like IBM Watson Health have formed strategic alliances with academic medical centers to enhance their AI-driven healthcare solutions. Through this practice, VCs can help their portfolio companies leverage external expertise and resources to advance their technologies and achieve commercial success.

Emphasize ethical AI.
To build trust and mitigate regulatory and public scrutiny risks, companies should prioritize transparency, accountability and fairness in their AI algorithms. This includes addressing patient privacy, data security, and algorithmic bias issues. VCs should seek companies with clear ethical guidelines and robust data governance frameworks. For example, companies like Google Health and Microsoft are known for their commitment to ethical AI practices, which enhances their reputation and market acceptance.

Support scalable solutions.
VCs should focus on companies that develop scalable solutions that can be easily integrated into existing healthcare infrastructures. Scalable innovations ensure broader adoption and maximize return on investment. Digitally transformed incumbents—those leveraging digital technologies to compete innovatively and those venturing into new industries digitally—are twice as likely to achieve outstanding financial growth compared to their traditional counterparts, as shown by a McKinsey study. VCs should assess the scalability potential of AI platforms, considering factors such as compatibility with existing systems, ease of implementation and cost-effectiveness. Companies that offer modular and flexible solutions, such as cloud-based platforms and API integrations, are well-positioned to scale their technologies and achieve widespread market penetration.

Conclusion
The fusion of AI and biotechnology presents a wealth of opportunities for venture capitalists. By staying attuned to emerging trends and adopting strategies for impactful investments, VCs can drive innovation and create transformative changes in healthcare.

